UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy
Brain and Behavior · 2025
DOI: 10.1002/brb3.70490 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Brain and Behavior, 2025. Verfasst von Isaac Cowley und 11 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Epilepsy, Medical Marijuana. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A third of epilepsy patients fail to enter seizure remission despite optimal therapeutic management. Cannabis‐based medicinal products (CBMPs) have shown promise as a potential therapy. However, a paucity of high‐quality literature regarding CBMPs’ efficacy and safety profile means further investigation is needed. The study aimed to examine changes in epilepsy‐specific and general health‐related quality of life (HRQoL) patient‐reported outcome measures (PROMs) in individuals with treatment‐resistant epilepsy.
Methods
A case series of patients with epilepsy from the UK Medical Cannabis Registry analyzed changes in Quality of Life in Epilpesy‐31 (QOILE‐31), Single‐Item Sleep Quality Score (SQS), EQ‐5D‐5L, Generalized Anxiety Disorder‐7 (GAD‐7) and Patient Global Impression of Change (PGIC) between baseline, one, three, and six months. Adverse events (AEs) were collected and classified by severity. p < 0.050 was considered statistically significant.
Results
There were 134 patients included. Improvements were recorded from baseline to one, three, and six months in QOILE‐31 and all HRQoL PROMs ( p < 0.050). Forty patients (29.85%) reported a minimal clinically important difference in Quality of Life in Epilepsy‐31 (QOLIE‐31) at six months. There were 18 (13.43%) AEs reported by 5 (3.73%) patients, mainly mild and moderate.
Discussion
The proportion of patients achieving a clinically significant change is similar to existing CBMPs in epilepsy literature. AE incidence was lower than similar studies although this may be due to the large proportion (67.16%) of individuals who were not cannabis naïve.
Conclusion
Initiation of CBMPs was associated with an improvement across all PROMs. CBMPs were well tolerated across the cohort. However, randomized controlled trials are needed to help determine causality. Clinical Trial Registration
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
- Curaleaf Clinic, London, UK.
- St. George's Hospital NHS Trust, London, UK.
- Department of Psychological Medicine, Kings College London, London, UK.
- South London and Maudsley NHS Foundation Trust, London, UK.
- Buckinghamshire Healthcare NHS Trust, Amersham, UK.
ORCID-Profile: Simon Erridge, Lilia Evans
Zitieren
APA
Cowley, I., Erridge, S., Aggarwal, A., Evans, L., Varadpande, M., Clarke, E., McLachlan, K., Coomber, R., Iqbal, A., Rucker, J. J., Weatherall, M. W., & Sodergren, M. H. (2025). UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy. Brain and Behavior. https://doi.org/10.1002/brb3.70490
Vancouver
Cowley I, Erridge S, Aggarwal A, Evans L, Varadpande M, Clarke E, et al. UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy. Brain and Behavior. 2025. doi:10.1002/brb3.70490
BibTeX
@article{Cowley2025,
author = {Cowley, Isaac and Erridge, Simon and Aggarwal, Arushika and Evans, Lilia and Varadpande, Madhur and Clarke, Evonne and McLachlan, Katy and Coomber, Ross and Iqbal, Augustin and Rucker, James J and Weatherall, Mark W and Sodergren, Mikael H},
title = {UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70490}
}
EUVIMED